Company: SXTPW
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003343
Chunk: 959

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 3
Chunk 959
---
1,678 Tradeable Warrants and 1,678 Non-tradeable Warrants. The Company also issued to the underwriters warrants
to purchase 1,416 shares of the Company’s common stock, at an exercise price of $349.80 per share, equal to 110% of the offering
price per unit (the “IPO Representative Warrants”). The IPO Representative Warrants are exercisable for a period of five
years from the date of issuance (July 14, 2023 to July 14, 2028).

The units were offered and sold pursuant to the
Company’s Registration Statement on Form S-1, as amended (File No. 333-269483), originally filed with the Securities and Exchange
Commission (the “SEC”) on January 31, 2023 (the “IPO Registration Statement”) and the final prospectus filed
with the SEC pursuant to Rule 424(b)(4) of the Securities Act of 1933, as amended. The Registration Statement was declared effective
by the SEC on July 11, 2023. The common stock and tradeable warrants began trading on The Nasdaq Capital Market on July 12, 2023 under
the symbols “SXTP” and “SXTPW,” respectively. The closing of the IPO occurred on July 14, 2023.

Risks and Uncertainties

The Company is subject to risks common to companies
in the biopharmaceutical industry including, but not limited to, the risks associated with developing product candidates and successfully
launching and commercializing its drug/device combination products, the Company’s ability to obtain regulatory approval of its
such products in the United States and other geography markets, the uncertainty of the broad adoption of its approved products by physicians
and consumers, and significant competition.

F-8

In addition, higher rates of inflation have resulted
in the U.S. Federal Reserve raising interest rates. Increases in interest rates, especially if coupled with reduced government spending
and volatility in financial markets, may further increase economic uncertainty and heighten these risks. Furthermore, if additional banks
and financial institutions enter receivership or become insolvent in the future in response to financial conditions affecting the banking
system and financial markets, the Company or its partners’ ability to access existing cash, cash equivalents and investments may
be threatened and could have a material adverse effect on the Company’s business and financial condition, including the Company’s
ability to access additional capital on favorable terms, or at